Literature DB >> 10022369

Design and analysis of serial limiting dilution assays with small sample sizes.

C Macken1.   

Abstract

We study the design of serial limiting dilution assays (SLDAs) for estimation of effector cell frequency in settings that restrict severely the amount of material available for assay, and for which the assumption of a single-hit Poisson model is reasonable. For different designs (that is, dilution factor, number of dilution levels, and number of replicates at each level), we evaluate maximum likelihood and minimum chi-square estimators, using four quantitative criteria: probability of a non-informative assay (PNI), bias, coefficient of variation (CV), and mean squared error (MSE). Our results are exact, not simulation-based, nor approximations. We found that differences between these two estimators were insubstantial by comparison with the effect on the estimators of the experimental design. Bias was severe in small assays, and could lead, in extremely small designs, to overestimation of effector frequency by as much as 100%. These four criteria provide a rigorous basis for determining the most effective apportionment of total effort among replicates and dilution levels. By increasing the dilution factor and favoring the number of replicates over the number of dilution levels, the PNI is reduced while bias, CV and MSE are increased; and vice versa. Our study is easily extended to estimation of the density of biologically active particles per volume. It can also be extended to alternatives to the single-hit Poisson model for a serial limiting dilution assay.

Entities:  

Mesh:

Year:  1999        PMID: 10022369     DOI: 10.1016/s0022-1759(98)00133-1

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  12 in total

1.  An anti-CD45RO immunotoxin kills HIV-latently infected cells from individuals on HAART with little effect on CD8 memory.

Authors:  J Saavedra-Lozano; Y Cao; J Callison; R Sarode; D Sodora; J Edgar; J Hatfield; L Picker; D Peterson; O Ramilo; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

2.  Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.

Authors:  Amanda M Crooks; Rosalie Bateson; Anna B Cope; Noelle P Dahl; Morgan K Griggs; JoAnn D Kuruc; Cynthia L Gay; Joseph J Eron; David M Margolis; Ronald J Bosch; Nancie M Archin
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

3.  Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.

Authors:  Nancie M Archin; Jennifer L Kirchherr; Julia Am Sung; Genevieve Clutton; Katherine Sholtis; Yinyan Xu; Brigitte Allard; Erin Stuelke; Angela D Kashuba; Joann D Kuruc; Joseph Eron; Cynthia L Gay; Nilu Goonetilleke; David M Margolis
Journal:  J Clin Invest       Date:  2017-07-17       Impact factor: 14.808

4.  SLDAssay: A software package and web tool for analyzing limiting dilution assays.

Authors:  Ilana M Trumble; Andrew G Allmon; Nancie M Archin; Joseph Rigdon; Owen Francis; Pedro L Baldoni; Michael G Hudgens
Journal:  J Immunol Methods       Date:  2017-07-18       Impact factor: 2.303

5.  Quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells.

Authors:  Natalia Soriano-Sarabia; Rosalie E Bateson; Noelle P Dahl; Amanda M Crooks; JoAnn D Kuruc; David M Margolis; Nancie M Archin
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

6.  Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.

Authors:  Ginger Lehrman; Ian B Hogue; Sarah Palmer; Cheryl Jennings; Celsa A Spina; Ann Wiegand; Alan L Landay; Robert W Coombs; Douglas D Richman; John W Mellors; John M Coffin; Ronald J Bosch; David M Margolis
Journal:  Lancet       Date:  2005 Aug 13-19       Impact factor: 79.321

7.  A two-stage experimental design for dilution assays.

Authors:  Jake M Ferguson; Tanya A Miura; Craig R Miller
Journal:  Biometrics       Date:  2019-04-03       Impact factor: 2.571

8.  Induction of Mycobacterium tuberculosis-specific primary and secondary T-cell responses in interleukin-15-deficient mice.

Authors:  Vanja Lazarevic; David J Yankura; Sherrie J DiVito; JoAnne L Flynn
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

9.  HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.

Authors:  Julia A Sung; Shabnum Patel; Matthew L Clohosey; Lauren Roesch; Tamara Tripic; JoAnn D Kuruc; Nancie Archin; Patrick J Hanley; C Russell Cruz; Nilu Goonetilleke; Joseph J Eron; Clio M Rooney; Cynthia L Gay; Catherine M Bollard; David M Margolis
Journal:  Mol Ther       Date:  2018-09-21       Impact factor: 11.454

10.  Quantification system for the viral dynamics of a highly pathogenic simian/human immunodeficiency virus based on an in vitro experiment and a mathematical model.

Authors:  Shingo Iwami; Benjamin P Holder; Catherine A A Beauchemin; Satoru Morita; Tetsuko Tada; Kei Sato; Tatsuhiko Igarashi; Tomoyuki Miura
Journal:  Retrovirology       Date:  2012-02-25       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.